The Advisory Board Company
The Daily Briefing
Whether you are determined to deliver on your strategic plan for 2012 or make the most of your incentive payments, we have a tool for you. View the ten most popular analytic tools of 2011.
January 04, 2012 (10:51 AM)
A surgeon's much-discussed essay in the Wall Street Journal has won plaudits for honesty, but drawn criticism for sharing unnecessary details and reinforcing stereotypes about physician behavior.
January 04, 2012 (5:00 AM)
CMS on Tuesday named 73 health care experts who will serve as "Innovation Advisors" and support individuals who are test-driving innovative payment and delivery models.
January 04, 2012 (10:09 AM)
Taking a provocative position on cost control, the American College of Physicians is urging physicians to be ethical by practicing "parsimonious" treatment.
January 04, 2012 (5:30 AM)
A New York bill that would require new RNs to obtain a Bachelor of Science in Nursing degree within 10 years has rekindled the debate over minimum nurse licensure requirements.
January 04, 2012 (4:00 AM)
Although many hospitals are eager to implement new mobile technologies, several challenges are hindering more widespread adoption of tablet computers, Kaiser Health News/NPR reports.
January 04, 2012 (4:30 AM)
President Obama on Dec. 23 signed a two-month extension of the payroll tax cut that includes a two-month delay to scheduled Medicare reimbursement cuts for physicians.
January 04, 2012 (10:37 AM)
CMS will postpone its Recovery Audit Prepayment Review demonstration project after receiving numerous critical comments about the program.
January 04, 2012 (9:53 AM)
Just eight votes separated Mitt Romney from runner-up Rick Santorum at Tuesday's Iowa caucuses, and the close race reflects the major ideological divide on issues like health care in the GOP presidential race.
Bite-sized hospital and health industry news from California, Connecticut, Illinois, and Massachusetts.
Bite-sized hospital and health industry news
Daily roundup: Jan. 4, 2012
Two new studies found that Genentech's cancer drug Avastin did not extend the lives of ovarian cancer patients, although it slowed progression of the cancer for a short time. More
Join the conversation on Twitter
